Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 4, 2017

Primary Completion Date

February 7, 2023

Study Completion Date

February 5, 2024

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

pembrolizumab

anti PD-1

Trial Locations (10)

M20 4BX

The Christie NHS Foundation Trust, Manchester

SO16 6YD

Southampton University Hospitals NHS Trust, Southampton

ME16 9QQ

Maidstone and Tunbridge Wells NHS Trust, Maidstone

B15 2TH

University Hospital Birmingham NHS Foundation Trust, Birmingham

CF14 2TL

Velindre Cancer Centre, Cardiff

Unknown

Western General Hospital, Edinburgh

LN2 5QY

United Lincolnshire Hospitals NHS Trust, Lincoln

E1 1BB

Barts Health NHS Trust, London

NW1 2BU

University College London Hospitals, London

SW3 6JJ

The Royal Marsden Hospital, London

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Birmingham

OTHER

NCT02733159 - Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2 | Biotech Hunter | Biotech Hunter